Abstract
ABSTRACT Heterotrophic Bacillus amyloliquefaciens (MTCC 12716) isolated from the red alga Hypnea valentiae exhibited promising antibacterial activity (minimum inhibitory concentration of ≤1.0 µg/mL) against clinically relevant pathogens. The bacterium displayed bile salt and acid tolerance up to 4 h in a simulated gastric fluid, along with a prospective antioxidant effect. This non-hemolytic bacterium was found to be sensitive to a panel of antibiotics and did not amplify the enterotoxin-specific genes. In order to analyze the possibilities of scaling up, we have optimized the growth of B. amyloliquefaciens by response surface methodology to realize maximum production of anti-infective agents in the fermentation medium and observed an increment of about 85% antibacterial activity against gastrointestinal pathogens. As probiotic treatment is useful due to its ability to recreate the natural intestinal microflora, this heterotrophic Bacillus could be contemplated to offer a prospective probiotic. Further studies are needed to assess its utility for commercial application.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
